Open Access. Powered by Scholars. Published by Universities.®
Female Urogenital Diseases and Pregnancy Complications Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- PASD (2)
- Placenta accreta spectrum disorder (2)
- Placenta percreta (2)
- Postpartum (2)
- Balloon occlusion (1)
-
- Bradycardia (1)
- Case report (1)
- Deep vein thrombosis (1)
- End-stage renal disease (1)
- FGN (1)
- GDM (1)
- Gestational diabetes mellitus (1)
- Glomerulonephritis (1)
- Glucose testing (1)
- Hematometra (1)
- Hepatitis C (1)
- Ketoacidosis (1)
- Kidney diseases (1)
- Preeclampsia (1)
- Pregnancy (1)
- Pregnancy complications (1)
- Pulmonary embolism (1)
- Quality improvement (1)
- RATG (1)
- Renal transplant (1)
- Starvation ketoacidosis (1)
- Surgical protocol (1)
- Type 2 diabetes (1)
- Uterine diseases (1)
- VTE (1)
Articles 1 - 8 of 8
Full-Text Articles in Female Urogenital Diseases and Pregnancy Complications
Prophylactic Resuscitative Endovascular Balloon Occlusion In The Management Of Placenta Percreta: A Case Report, Monica Rodriguez, Nicole Tenzel, Rachel Russo, Robert Cohen
Prophylactic Resuscitative Endovascular Balloon Occlusion In The Management Of Placenta Percreta: A Case Report, Monica Rodriguez, Nicole Tenzel, Rachel Russo, Robert Cohen
North Texas Research Forum 2025
Introduction: Placenta accreta spectrum disorders (PASD) are associated with severe maternal morbidity, including hemorrhage requiring massive transfusion, intensive care unit (ICU) admission, coagulopathy, organ ischemia or failure, and death. The adherent placenta results in continuous mixed arterial and venous bleeding, preventing the uterus from adequately contracting. This can result in a blood loss rate of 600 mL or more per minute, posing a risk of exsanguination in less than five minutes. Few reports exist on the prophylactic use of resuscitative endovascular balloon occlusion of the aorta (REBOA) to reduce obstetric hemorrhage and its application for prolonged occlusion times exceeding 60 …
A Standardized Surgical Protocol For Placenta Accreta Spectrum Disorder At An Accreta Center Of Excellence, Ana Adams, Monica Rodriguez, Kate Hansen, Aysu Erdemir, Robert Cohen
A Standardized Surgical Protocol For Placenta Accreta Spectrum Disorder At An Accreta Center Of Excellence, Ana Adams, Monica Rodriguez, Kate Hansen, Aysu Erdemir, Robert Cohen
North Texas Research Forum 2025
Introduction Placenta Accreta Spectrum Disorder (PASD) refers to a spectrum of abnormal invasion of the placenta into the uterus during pregnancy. PASD ranges in severity from involvement through the endometrial layer of the uterus to complete invasion involving other pelvic structures. This abnormal invasion can result in significant postpartum hemorrhage, often requiring large-volume transfusions, about six units of packed red blood cells on average. The maternal mortality rate associated with PASD is approximately 4-7%. The Society for Maternal-Fetal Medicine (SMFM) recommends that pregnancies complicated by PASD be delivered in hospitals with dedicated interdisciplinary teams, referred to as “Accreta Centers of …
Postpartum Glucose Testing And Primary Care Follow-Up For Women With Gestational Diabetes Mellitus: A Quality Improvement Project, Madeline Bartram, Anusha Hussain, Timothy Kremer
Postpartum Glucose Testing And Primary Care Follow-Up For Women With Gestational Diabetes Mellitus: A Quality Improvement Project, Madeline Bartram, Anusha Hussain, Timothy Kremer
North Texas Research Forum 2025
BACKGROUND: Patients with gestational diabetes mellitus (GDM) have a 40-70% lifetime risk for developing type 2 diabetes mellitus, which is 9 times the risk of patients without a history of GDM. Joint association guidelines recommend a 75-gram, 2-hour oral glucose tolerance test (GTT) at 4 to 12 weeks postpartum for all patients with GDM, and to follow-up with a primary care physician. Currently, less than half of these patients do not receive the recommended postpartum glucose testing and/or follow-up. METHODS: For each GDM-affected pregnancy, two primary outcome measures were retrospectively collected from the clinic EHR: completion of the 75-gram GTT …
Optimization Of Venous Thromboembolism (Vte) Prophylaxis In Pregnancy And The Postpartum Period, Sereena Jivraj, Isabella Sciacca, Sherrie Dixon, Timothy Kremer
Optimization Of Venous Thromboembolism (Vte) Prophylaxis In Pregnancy And The Postpartum Period, Sereena Jivraj, Isabella Sciacca, Sherrie Dixon, Timothy Kremer
North Texas Research Forum 2025
Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolisms (PE) continues to be a leading cause of maternal mortality (MM) in the United States. VTE accounts for roughly 9-10% of all maternal deaths. Other countries have adopted anticoagulation protocols to reduce MM rates, but the US has yet to follow suit. The American College of Obstetricians and Gynecologists (ACOG), the American College of Chest Physicians (CHEST), and the Royal College of Obstetricians and Gynaecologists (RCOG) all vary in their guidelines for thromboembolism prophylaxis. Patients who deliver by Cesarean section (C-section) have higher incidences of MM due …
Fibrillary Glomerulonephritis Associated With Hepatitis C: A Case Report Of Progression To End-Stage Renal Disease, Boney Lapsiwala, Karthik Kasireddy, Marisha Sharma, Mayank Singh, Vaishnavi Singh, Victor Canela
Fibrillary Glomerulonephritis Associated With Hepatitis C: A Case Report Of Progression To End-Stage Renal Disease, Boney Lapsiwala, Karthik Kasireddy, Marisha Sharma, Mayank Singh, Vaishnavi Singh, Victor Canela
North Texas Research Forum 2025
A Case of DNAJB9 with rapid renal progression to End-Stage Renal Disease in a patient with previously treated HCV Background Fibrillary glomerulonephritis (FGN) is a rare and progressive kidney disease, accounting for 0.5% to 1.4% of native kidney biopsies. It is characterized by non-amyloid fibrillar deposits in the extracellular matrix. Although historically regarded as idiopathic, recent studies have revealed associations with autoimmune diseases, malignancies, and Hepatitis C virus (HCV) infection. DNAJB9, a proteomic marker identified through mass spectrometry, has been consistently found in FGN cases, regardless of congophilia. This case illustrates FGN in a patient with a history of successfully …
Bradycardia In A Renal Transplant Patient Receiving Rabbit Antithymocyte Globulin, John Mathew, Victor Delprincipe, Seline Haci, Karthik Anand, Rangina Farhad
Bradycardia In A Renal Transplant Patient Receiving Rabbit Antithymocyte Globulin, John Mathew, Victor Delprincipe, Seline Haci, Karthik Anand, Rangina Farhad
North Texas Research Forum 2025
Rabbit antithymocyte globulin (rATG) is widely used for induction and treatment of acute T-cell mediated rejection in renal transplant patients. Bradycardia is reported as a rare side effect of this medication (citation). With the increasing number of transplanted kidneys in today's world, there is greater need to understand the adverse effects of these drugs in transplant recipients.. Here we report a case of symptomatic bradycardia in a renal transplant patient receiving rATG for acute T-cell mediated rejection.
Hematometra In A Pre-Menopausal Patient: A Case Report Of Idiopathic Cervical Occlusion, Sandra Zhi, Claire Middleton, Chrystal Stallworth, Mindy Beth Luck, Nicole Tenzel
Hematometra In A Pre-Menopausal Patient: A Case Report Of Idiopathic Cervical Occlusion, Sandra Zhi, Claire Middleton, Chrystal Stallworth, Mindy Beth Luck, Nicole Tenzel
North Texas Research Forum 2025
Introduction: Hematometra is a blood collection caused by a structural blockage of the vagina or cervix. Most cases of hematometra and/or hematocolpos occur in a relatively rare condition of imperforate hymen or Mullerian anomalies in children or adolescent patients. Case: We present a case of a 46 year old G2P2002 with a past surgical history of two C-sections with increasingly severe pelvic pain and abnormal uterine bleeding for the prior five years since her last Cesarean delivery. A large hematometra was found on CT imaging. Pelvic exam showed no vaginal abnormalities and a discolored, pale cervix. Digital pressure led to …
Treatment Of Starvation Ketoacidosis In The Third Trimester Of Pregnancy: A Case Report, Christine Le, Charmaine Oladell, Nicole Tenzel
Treatment Of Starvation Ketoacidosis In The Third Trimester Of Pregnancy: A Case Report, Christine Le, Charmaine Oladell, Nicole Tenzel
North Texas Research Forum 2025
INTRODUCTION: Starvation ketoacidosis represents a rare but complicated maternal morbidity that primarily occurs in the third trimester of pregnancy. With increased insulin resistance and metabolism manifesting in pregnancy, prompt care is required to diagnose and treat starvation ketoacidosis as it appears at an accelerated rate. However, despite the severity of maternal and fetal complications arising from this condition, standardized treatment protocols have not been elucidated. CASE PRESENTATION: In this case report, a 33-year-old gravida 3 para 0-2-0-2 at 31 weeks and 5 days gestational age was admitted to antepartum services for intractable nausea, vomiting, and anuria and transferred to the …